NCT06430801

Who might be able to join this trial:

• You have been diagnosed with Crohn's disease (CD) for at least 3 months before joining the study.
• Your Crohn's disease is considered moderately to severely active.
• Previous treatments have not worked well enough for you, stopped working, or caused side effects you could not tolerate — this includes steroids, immune-suppressing medications, or more advanced biologic or small molecule therapies.
• Teenagers aged 16 or 17 may be able to join, depending on approval in their country (confirm with trial site).

Who may not be able to join:

• You have been diagnosed with ulcerative colitis or indeterminate colitis instead of Crohn's disease.
• Your Crohn's disease only affects certain parts of the upper digestive tract or the area around the anus, without involving the large intestine or lower small intestine.
• You currently have serious complications of Crohn's disease, such as an abscess, a severe narrowing of the bowel, a severely inflamed colon, or a condition that may require surgery soon.
• You currently have or need a stoma bag (colostomy or ileostomy).
• Large portions of your bowel are missing (more than 2 out of 5 specific sections of your intestine).
• You have been diagnosed with short bowel syndrome or have another unrelated condition causing ongoing, uncontrolled diarrhea.
• You have had bowel surgery within the 3 months before joining the study.
• You have a history of abnormal or pre-cancerous cell changes in your digestive tract.
• You have a long-term infection that requires ongoing antibiotic or antimicrobial treatment.
• You have had cancer in the past or currently, unless it was a certain type of treatable skin cancer or a very early-stage cervical condition that was fully removed — and you must have been cancer-free for at least 5 years.
• You are currently infected with Hepatitis B, Hepatitis C, or HIV.
• You have active tuberculosis (TB).
• You currently have or are suspected to have COVID-19.
• You have previously received the specific experimental drug being tested in this trial (tulisokibart/MK-7240/PRA023) or a similar type of drug.

Important: Always verify eligibility with the trial site directly before applying.